What happened with AKBA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Akebia Therapeutics sells Auryxia and Vafseo to treat complications of chronic kidney disease. Auryxia, including its authorized generic, supplies most of the company’s revenue. It controls blood phosphorus in adults on dialysis and treats iron-deficiency anemia in adults with chronic kidney disease who are not on dialysis. Vafseo treats kidney-disease-related anemia; its U.S. approval is limited to adults who have received dialysis for at least three months. Product sales help fund development of additional medicines.
Akebia receives payment from dialysis organizations, distributors and specialty pharmacies that buy its medicines. DaVita, Fresenius Medical Care Rx and USRC together account for a substantial share of gross product revenue. Dialysis organizations’ drug formularies and treatment protocols influence whether patients receive the products, while Medicare and insurer reimbursement affects what buyers can afford to pay. For dialysis use, both medicines fall within Medicare’s bundled payment for treatment, with temporary additional reimbursement rather than permanent separate drug payments.
Auryxia has lost U.S. exclusivity, and Mylan Therapeutics distributes an authorized generic supplied by Akebia. The business therefore depends partly on retaining dialysis-organization contracts as generic competition develops. Akebia also outsources all manufacturing and relies on Cardinal Health as its exclusive logistics provider; Auryxia’s drug substance and finished tablets each depend on a single supplier.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Watch CSL Vifor: Akebia needs Vafseo to gain adoption against its Mircera while owing it sales-linked royalties and working-capital repayments.
Ardelyx's XPHOZAH competes for phosphorus treatment in adults on dialysis, as an add-on when phosphate binders such as Akebia's Auryxia are inadequate or intolerable. Watch Ardelyx's reimbursement appeal: success could remove Auryxia from Medicare's bundled dialysis payment and reduce Akebia's anticipated revenue.
Fresenius Medical Care pays Akebia for kidney medicines used in its dialysis network, but also sells PhosLo, Phoslyra and Velphoro against Auryxia. Its supply terms for Auryxia and Vafseo matter to Akebia's sales, making the dialysis-care provider both a buyer and a competitor.
DaVita buys Akebia's phosphorus-control drug Auryxia and anemia drug Vafseo for its large U.S. dialysis population, so its purchasing terms directly matter to Akebia's sales. Watch how DaVita incorporates Vafseo into treatment protocols, which can give eligible patients access to prescriptions.
Unicycive's experimental phosphorus-binding drug OLC would compete with Akebia's Auryxia for patients on dialysis if approved. Watch both FDA approval and whether Medicare grants separate add-on payments to dialysis providers for OLC, since reimbursement would influence their choice of medicine.
Amgen's Epogen and Aranesp compete with Akebia's Vafseo to treat kidney-disease anemia; Vafseo's U.S. use is limited to adults who have been on dialysis for at least three months. Amgen sells medicines largely through wholesalers in the U.S., so its Epogen and Aranesp sales are the relevant lines to watch rather than its whole drug portfolio.
Teva's generic Auryxia could directly pressure Akebia's largest product-revenue source, but its January 22, 2026 FDA approval was only tentative. Watch final approval and launch, then the generic's pricing and dialysis-organization contracts, which will shape the impact on Auryxia revenue.
Travere's marketed FILSPARI already treats IgA nephropathy, a market Akebia hopes to enter with AKB-097, and its pursuit of focal segmental glomerulosclerosis also overlaps Akebia's rare-kidney-disease pipeline markets. Watch FILSPARI's use in IgA nephropathy and its FDA review for focal segmental glomerulosclerosis to gauge the treatment landscape Akebia faces.
Q32 Bio sold Akebia the assets behind ADX-097, now AKB-097, leaving Akebia responsible for developing and commercializing the experimental medicine. Success would also mean payments to Q32 Bio through development, regulatory and commercial milestones and royalties on annual net sales.
Fed Interest Rate Decision
For Akebia, the Fed’s policy-rate decision matters because higher rates can raise interest on its BlackRock loan, which resets with one-month SOFR, leaving less cash for its kidney medicines and development programs.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed’s rate is higher than expected, rising market rates could increase interest paid on Akebia’s floating-rate loan and leave less cash for selling Vafseo and Auryxia and advancing its programs; the loan’s 15% annual cap limits the increase.
If it comes in below expectations
If the Fed’s rate is lower than expected, falling market rates could reduce interest paid on Akebia’s floating-rate loan and leave more cash for selling Vafseo and Auryxia and advancing its programs; the loan’s 4.25% SOFR floor limits the decrease.
Ardelyx, Inc. earningsARDX
Ardelyx’s report can show demand for XPHOZAH among dialysis patients and whether reported reimbursement developments could affect Akebia’s Auryxia.
Watch XPHOZAH use and any reported progress on Ardelyx’s reimbursement appeal. Greater use would signal stronger competition for phosphate treatment in dialysis; if an appeal outcome changes Auryxia’s treatment under Medicare’s bundled dialysis payment, facilities’ reimbursement conditions would change too, while no change would leave Akebia facing the existing bundled-payment environment.
DaVita Inc. earningsDVA
DaVita’s report can show how the large dialysis provider buys Akebia’s medicines and whether Vafseo is reaching more patients through its treatment protocols.
Look for DaVita’s disclosures on medicine purchasing and Vafseo’s place in treatment protocols. Wider use for eligible patients alongside steady Auryxia purchases would give Akebia a firmer sales route through this major customer; limited adoption or weaker purchases would leave its reliance on a small group of dialysis organizations exposed.
Amgen Inc earningsAMGN
Amgen’s Epogen and Aranesp compete with Akebia’s Vafseo for dialysis patients with kidney-disease anemia, and this report can show how strong those established alternatives remain.
Focus on any separate sales disclosures for Epogen and Aranesp, not Amgen’s overall results. Resilient sales would show that Vafseo still faces established alternatives; weaker sales could ease that pressure, but would not prove patients are switching to Vafseo, so read them alongside Akebia’s disclosures on Vafseo adoption.
Teva Pharmaceutical Industries Limited earningsTEVA
If Teva’s generic Auryxia receives final approval and launches, it will compete directly with Akebia’s largest source of product revenue.
Watch for any disclosure of final approval, launch, pricing or dialysis-organization contracts for Teva’s generic Auryxia. A launched product with sales would bring more direct price and access competition for Akebia’s Auryxia revenue; if it has not launched, Teva has not yet added active commercial pressure, though the existing authorized generic still competes.
Akebia Therapeutics, Inc. earningsThis company
Akebia relies on Auryxia and Vafseo sales to support its commercial business, and this report will show whether Vafseo can offset pressure on Auryxia from generic competition.
Read Vafseo and Auryxia product revenue together, then check how product costs change. Rising Vafseo revenue with steady Auryxia sales—and costs the business can absorb as Vafseo moves to full manufacturing cost—would show the newer drug is sharing the load; weak Vafseo growth, falling Auryxia sales and higher costs would leave less room for Akebia’s commercial business to support its programs.
